
Healthcare Picks Sides in Hepatitis C Drug Battle
Since Express Scripts announced its exclusivity agreement with AbbVie for its hepatitis C drug, other pharmacy benefits managers and insurers have picked sides. But are the deals a good thing?
Just days after regulators had approved AbbVie’s Viekira Pak and provided real competition for Gilead Science’s expensive hepatitis C treatments, Express Scripts announced an exclusivity agreement with AbbVie in exchange for a lower price.
Others followed suit.
Gilead’s Harvoni costs $94,500 for a 12-week course of treatment; however, most patients will be able to take the 8-week course for $63,600. Viekira Pak’s 12-week course costs $83,319. While the presence of a competitor can benefit patients as insurers negotiate lower prices, some are concerned that these exclusivity deals can be harmful because: 1) treatment decisions are being taken
AdverseEvents, a California-based healthcare informatics company that analyzes drug side effect data, recently
While both Viekira Pak and Harvoni list fatigue, headache, nausea, diarrhea, insomnia, and bilirubin elevations as adverse events, Viekira Pak has a long list of adverse events that are absent from Harvoni’s label, including anemia, jaundice, liver inflammation, loss of therapeutic effect, and ulcer. The only additional adverse event listed on Harvoni’s label that is not on Viekira Pak’s is lipase elevations.
So far Express Scripts is the only company to make an exclusivity agreement with AbbVie’s drug. Meanwhile, Prime Therapeutics LLC chose not to pick a side. Instead the pharmacy benefits manager made agreements with both Gilead and AbbVie and will place both Harvoni and Viekira Pak on the preferred drug list,
“There has been a substantial reduction in the net price of both of these drugs just in the past few weeks, so sometimes it pays not to go first,” Peter Wickersham, senior vice president of Integrated Care and Specialty at Prime
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.